Introduction
============

Morphine is a powerful analgesic agent used for treating acute and chronic pain in surgical interventions or in hospice care ([@b1-ijmm-43-02-0791]). However, long-term administration of morphine induces tolerance and hyperalgesia. Furthermore, adverse effects, including addiction, dependence, constipation and respiratory depression limit its clinical usefulness ([@b2-ijmm-43-02-0791],[@b3-ijmm-43-02-0791]). The physiological responses of morphine tolerance include opioid receptor uncoupling, endocytosis/desensitization ([@b4-ijmm-43-02-0791]), increased binding of β-arrestin to opioid receptors, glutamatergic receptor activation and neuroinflammation ([@b5-ijmm-43-02-0791]). Melatonin is a neurohormone derived from serotonin and is released from the pineal gland ([@b6-ijmm-43-02-0791]). It is used for sleep modulation and relieves the stress caused by sleep disturbance ([@b1-ijmm-43-02-0791]). It has previously been revealed that melatonin treatment partially reverses morphine tolerance by inhibiting microglia activation though a heat shock protein 27 (HSP27)-associated pathway ([@b7-ijmm-43-02-0791]). Furthermore, melatonin co-treatment was revealed to prevent morphine-induced hyperalgesia and tolerance in rats, potentially by inhibiting protein kinase C-associated pathways ([@b8-ijmm-43-02-0791],[@b9-ijmm-43-02-0791]). A report also demonstrated that decreased mitochondrial DNA copy numbers in the hippocampus during opiate addiction were mediated by autophagy and may be reversed by melatonin ([@b10-ijmm-43-02-0791]). Additionally, melatonin was revealed to enhance the reward behaviour of morphine via the nitric oxidergic pathway ([@b11-ijmm-43-02-0791]). Raghavendra and Kulkarni initially reported that the systemic administration of melatonin reversed morphine-induced tolerance in mice ([@b12-ijmm-43-02-0791]). Song *et al* ([@b8-ijmm-43-02-0791]) identified that daily intraperitoneal melatonin treatment reduced morphine tolerance in rats via the regulation of the N-methyl-D-aspartate receptor subunit 1. Furthermore, Garmabi *et al* ([@b13-ijmm-43-02-0791]) observed a reduction of melatonin levels in rats under constant light exposure; those animals also presented a high morphine consumption and severe morphine withdrawal syndrome. Fan *et al* ([@b14-ijmm-43-02-0791]) further reported a substantial decrease of serum melatonin and melatonin receptor 1 mRNA subsequent to chronic morphine infusion in rats. Previously, not only was it revealed that melatonin treatment partially reversed morphine tolerance by inhibiting microglia activation though a HSP27-associated pathway ([@b7-ijmm-43-02-0791]), but preliminary examinations additionally revealed that chronic morphine treatment resulted in transcriptomics changes. All studies noted that melatonin participates in the morphine tolerance pathway. Although melatonin was demonstrated to diminish morphine tolerance, the transcriptomic changes derived from melatonin treatment in opiate tolerance remain undetermined. To search whole genome expression profiles disturbed by long-term morphine administration and clarify the gene alterations caused by melatonin, an expression array was used in the present study to examine the effects of melatonin treatment on morphine-induced tolerance in rats. The results may provide insight on and contribute to deciphering the detailed mechanisms of morphine tolerance.

Materials and methods
=====================

Construction of intrathecal catheters
-------------------------------------

The intrathecal (i.t.) catheters were constructed by inserting a 3.5 cm Silastic tube (Corning Incorporated, Corning, NY, USA) into an 8 cm polyethylene tube (0.008 inch internal diameter, 0.014 inch outer diameter; Spectranetics, Colorado Springs, CO, USA) and sealing the joint with epoxy resin and silicon rubber as previously described ([@b15-ijmm-43-02-0791]).

Animal preparation and intrathecal drug delivery
------------------------------------------------

The use of rats in the present study adhered to the Guiding Principles in the Care and Use of Animals of the American Physiology Society ([@b16-ijmm-43-02-0791]) and was ethically approved by the National Defense Medical Center Animal Care and Use Committee (Taipei, Taiwan). A total of 27 Male Wistar rats (350-400 g), each rat (with 12 weeks of age) was housed individually at a room temperature at 25°C, at 1 atm, with water and food freely as wish. The rats were anaesthetized with phenobarbital (65 mg/kg, intraperitoneally) and two i.t. catheters were implanted. The catheters were inserted via the atlantooccipital membrane down to spinal cord segments L5, L6 and S1-S3, which are associated with the tail-flick reflex ([@b17-ijmm-43-02-0791]). One catheter was connected to a mini-osmotic pump (Alzet, Cupertino, CA, USA) for an infusion of saline or morphine (15 *µ*g/h) for 7 days at a rate of 1 *µ*l/h. Subsequent to cath-eterization (day 0), the rats were returned to their home cages and maintained in a 12 h light/dark cycle with *ad libitum* access to food and water. Rats with neurological deficits were excluded. On day 7, by which time a morphine tolerance had developed, the catheter used for saline or morphine infusion was cut and blocked with a metal metal plug to prevent CSF leakage. The rats were injected i.t. via the second catheter with 5 *µ*l either with vehicle (10% ethanol) or melatonin (50 *µ*g in 10% ethanol), then, 30 min later, a single dose of morphine (15 *µ*g in 5 *µ*l saline, i.t.) was injected and the antinociceptive effect measured. The protocol is presented in [Fig. 1A](#f1-ijmm-43-02-0791){ref-type="fig"}. There were four experimental groups used in the present study, as follows: Controls, melatonin-treated, morphine-treated and those treated with melatonin and morphine combined. For the control group, the animals were infused with saline for 7 days and infused with vehicle injection for 30 min, and subsequently injected with saline. For the morphine group, the animals were infused with morphine for 7 days, injected with vehicle injection for 30 min and subsequently injected with morphine. For the melatonin group, the animals were infused with morphine for 7 days and injected with melatonin for 30 min, and subsequently injected with saline. For the melatonin and morphine group, the animals were infused with morphine for 7 days, injected with melatonin for 30 min and subsequently injected with morphine.

The dose of morphine selected was based on a previous study ([@b18-ijmm-43-02-0791]). For i.t. injection, melatonin was dissolved in ethanol (50 *µ*g/5 *µ*l in 10% ethanol maximum). All drugs were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) and were delivered i.t., followed by the flushing of the catheter with 5 *µ*l saline. Preliminary results revealed no abnormal motor function subsequent to i.t. injection of the test drugs (data not shown).

Antinociception test
--------------------

Tail-flick latency was measured using the hot water immersion test (52±0.5°C). Baseline latency was \~2±0.38 sec, and a cutoff time of 10 sec was used. Rats were placed in plastic restrainers for drug injection and antinociception testing.

Spinal cord sample collection from rats with different treatments
-----------------------------------------------------------------

Spinal cord sample collection was performed as previously described ([@b7-ijmm-43-02-0791]), and morphine tolerance in rats was confirmed by the time-course of tail-flick latency over a 7-day period. Prior to day 4, the rats with morphine infusions demonstrated a reduction of tail-flick latency compared with the saline-infused group, which exhibited no changes in latency during the period. Substantial morphine tolerance was developed on day 7 as determined by a significant reduction of the antinociceptive effect of morphine compared with day one, with a reduction of the tail-flick latency of \~60%. And then, rats were i.t. injected with either 10% ethanol (as a vehicle) or melatonin via the externalized i.t. catheter. A total of 30 min later, a single dose of morphine (15 *µ*g) was injected i.t. to confirm morphine tolerance. In contrast, melatonin pretreatment attenuated morphine tolerance, melatonin pretreatment was done by administering melatonin on day 7, at 30 min prior to morphine intrathecal injection. The lumbar enlargement segment was removed from 4 rat spinal cords from each group for differential gene expression analysis.

Spinal cord sample preparation
------------------------------

Following drug treatment, the rats were sacrificed by exsanguination under anaesthesia with isoflurane (Abbott Pharmaceutical Co. Ltd., Lake Bluff, IL, USA) and a laminectomy was performed at the lower edge of the 12th thoracic vertebra. Subsequently, the lumber enlargement (L5-S3) of the spinal cord was immediately collected for subsequent analysis.

Rat expression microarray
-------------------------

Following the tail-flick test, the rats were sacrificed, and lumber enlargement (L5-S3) of the spinal cord was immediately collected. There were 4 samples tested in each group. Total mRNAs were extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). RNA concentration and purity were assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA) with a criteria of OD260/OD280 (\>1.8) and OD260/OD230 (\>1.6). Next, the RNAs were labelled with Cy5 dye by an indirect NHS ester labelling kit (GE Healthcare, Chicago, IL, USA) according to the manufacturer's protocol. The labelled RNAs were hybridized with a Rat OneArray^®^ microarray (Phalanx Biotech Group, Hsinchu, Taiwan), which contains 24,358 rat genome probes and 980 experimental control probes. All the probes correspond to annotated genes in RefSeq and Ensembl databases. The hybridization procedure was performed at 50°C in a Phalanx Hybridization System (Phalanx Biotech Group). A total of 16 h after hybridization, non-specific binding targets were washed away using three sequential washing steps by 2X saline-sodium citrate buffer (SSC) contained 0.2% SDS solution for 5 min at 42°C. Then, the slide was spun dry with a centrifuge for 1 min at room temperature. The images of the microarray were scanned using an Agilent G2505C scanner (Agilent Technologies, Inc.). The Cy5 fluorescence intensities of each spot were analysed by GenePix 4.1 software (Molecular Devices, LLC, Sunnyvale, CA, USA).

Microarray analysis
-------------------

Microarray spot analysis was resolved by the Rosetta Resolver System^®^ (Rosetta Biosoftware, Seattle, WA, USA). Control probes data were calculated, and the reproducibility of each microarray slide was assessed using Pearson's correlation coefficient calculations with a criterion of R-value \>0.975. Normalized spot intensities were transformed to gene expression log~2~ ratios in each group. For further analysis, the spots with a log~2~ ratio ≥1 or a log~2~ ratio ≤−1 or undetectable log~2~ ratios but with differences in intensity between the two samples of \>1,000 and a P\<0.05 were selected according to the method of Pirooznia *et al* ([@b19-ijmm-43-02-0791]). Principal Component Analysis (PCA) was performed to evaluate any differences among biological replicates and their treatment conditions using FDA released ArrayTrack™ HCA-PCA Standalone Package ([@b20-ijmm-43-02-0791]). PCA uses an orthogonal transformation to convert a set of observations of possibly correlated variables into a set of values of uncorrelated variables called principal components. For advanced data analysis, intensity data were pooled and calculated to identify differentially expressed genes based on the threshold of fold-change and P-value. The correlation of expression profiles between samples and treatment conditions was demonstrated by unsupervised hierarchical clustering analysis. Average linkage clustering was performed to visualize the correlations among the replicates and varying sample conditions using and open source software, Java Treeview ([@b21-ijmm-43-02-0791]). Up and downregulated genes are represented in red and green colors, respectively.

Gene ontology (GO) enrichment analysis
--------------------------------------

The gene IDs of interest were uploaded to the Gene ontology Enrichment analysis website ([@b22-ijmm-43-02-0791]). The database and analysis services were funded by the National Human Genome Research Institute in the U.S. And right now the website were maintained and updated by the Gene Ontology Consortium (GOC). The names of the genes with interested were paste to the query column in the website and set the GO aspect as molecular function for the analysis. The database search was confined to *Rattus norvegicus* database.

Gene pathway mapping by PANTHER
-------------------------------

The gene IDs of interest were uploaded to the PANTHER Classification System website (<http://pantherdb.org>). PANTHER is a comprehensive, curated database of protein families, trees, subfamilies, functions and ontology ([@b23-ijmm-43-02-0791]). The search parameter was set to 'molecular function', and the database search was confined to only the *Rattus norvegicus* database. The keywords used were the gene names of interest and the access date were December 12 and 19, 2017.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
-----------------------------------------------------------------------------------------

Tissues were collected as described above. RNA was extracted within 1 h at room temperature using TRIzol reagent following manufacturer's protocol (Invitrogen; Thermo Fisher Scientific, Inc.). mRNA were reverse transcribed to cDNA using the SuperScript III First-Strand Synthesis System (Invitrogen; Thermo Fisher Scientific, Inc.). cDNA were amplified and subjected to optical analysis to verify the integrity of extracted RNA. The expression of target genes were quantified for all experimental groups using LightCycler system (Roche Diagnostics, Basel, Switzerland). RT-qPCR analysis thermocycling conditions were: 95°C for 10 min and then the cycling conditions were set as 95°C for 10 sec, 60°C for 20 sec, 72°C for 40 sec for 50 cycles. The method of quantification for RT-qPCR products were followed Livak and Schmittgen *et al* ([@b24-ijmm-43-02-0791]) The relative abundance of transcripts were normalized to the constitutive expression of GAPDH. The primers of each genes used in RT-qPCR were listed in [Table I](#tI-ijmm-43-02-0791){ref-type="table"}.

Data and statistical analyses
-----------------------------

All data are presented as the mean ± standard error of the mean. Statistical analysis was performed using SigmaStat 3.0 software (SYSTAT Software Inc., San Jose, CA, USA). Tail-flick latencies were analyzed using two-way (time and treatment) analysis of variance (ANOVA), followed by one-way ANOVA with a *post hoc* Student-Newman-Keuls test. The RT-qPCR results were analyzed using a Student's t-test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Experimental design and procedure
---------------------------------

The experimental procedure for drug administration was depicted in [Fig. 1](#f1-ijmm-43-02-0791){ref-type="fig"}. Male Wistar rats were implanted with two i.t. catheters and connected to a mini-osmotic pump for morphine or saline infusion for 7 days for morphine tolerance induction. On day 7, subsequent to the development of tolerance, the catheter was cut, and 3 h later, the rats received an i.t. injection of either vehicle or melatonin via the other catheter. A total of 30 min later, at the tolerance expression phase, a single dose of morphine (15 *µ*g) was injected i.t., and the antinociceptive effect was measured. Tail flick tests were performed in every experimental group and the results were presented in [Fig. 1B](#f1-ijmm-43-02-0791){ref-type="fig"}. There was a significant reduction of morphine tolerance subsequent to melatonin addition compared with the control group (P\<0.01). Following a tail-flick test, the rats were sacrificed, and the L5 to S3 region of the spinal cords were collected for further analysis.

Differential gene expression among morphine tolerance, melatonin treatment and morphine tolerance combined with melatonin treatment groups
------------------------------------------------------------------------------------------------------------------------------------------

To determine the alterations in gene expression caused by morphine and reversed by melatonin treatment in rat spinal cords, rat global gene expression profiles of four independent RNA samples from each group were selected for microarray analysis. PCA and clustering analysis revealed that the overall gene profiles derived from microarray analysis were separated based on morphine or melatonin treatment. The result revealed that 162 genes were upregulated and 16 genes were downregulated in the morphine-tolerant group (MO group, n=7) compared with the control group (C group, n=5); 476 genes were upregulated and 71 genes were downregulated in the melatonin treatment group (Ma group, n=5) compared with the control group (C group), and 290 genes were upregulated and 15 genes were downregulated in the morphine with acute melatonin treatment group (MOMa group, n=10) compared with the control group ([Table II](#tII-ijmm-43-02-0791){ref-type="table"}). All genes selected using the criteria of log~2~\|Fold change\|≥ 1 and P\<0.05 or undetectable log~2~ ratios but with differences in intensity between the two samples of \>1,000. Statistical significance was used to avoid confounding due to variation amongst the animals and addressed additional evidence that the transcriptional profiles of morphine tolerance and melatonin treatment *in vivo* are different. The present study compared the number of upregulated genes between the MO and MOMa groups; it was identified that the number of upregulated genes in the MOMa group was greater compared with the number in the MO group, which indicated that melatonin restored the antinociceptive effect of morphine, which was accomplished with multiple gene expression alterations.

Gene ontology (GO) analysis of the altered genes from the MO or MOMa group
--------------------------------------------------------------------------

The differentially expressed genes were then subjected to GO analysis based on molecular function ([Table III](#tIII-ijmm-43-02-0791){ref-type="table"}). Numerous GO terms were identical between the two groups; however, opsonin binding, actin binding, calcium ion binding, sugar binding, oxidase activity, deaminase activity, protein complex binding and oxidoreductase activity were not identified in the MO group. On the other hand, GTPase activity, phospholipase inhibitor activity, cytokine activity, GTP binding, guanyl-nucleotide and ribonucleotide binding, immunoglobulin (Ig)G receptor activity, IgE binding and protein dimerization activity were not identified in the MOMa group, implying the potential regulatory mechanism of melatonin treatment. From the GO terms identified between the MO and MOMa groups, it was revealed that a number of notable pathways were altered. It has been previously reported that the morphine tolerance process involves inflammation ([@b25-ijmm-43-02-0791]). Immune-associated processes, including cytokine activity, IgG receptor activity and IgE binding, were missing following melatonin treatment, which indicates that melatonin treatment may participate in the downregulation of these cellular process. On the other hand, the gene expression for actin binding was present following melatonin treatment; this result implies that cytoskeleton reconstitution may be activated. Additionally, genes involving calcium ion binding, sugar binding, NADPH oxidase activity, deaminase activity and protein complex binding pathways appeared subsequent to melatonin treatment, indicating the requirement for the metabolic activity that emerged following melatonin treatment. The gene expression data for IgG receptor expression and actin binding were selected and provided by request.

Venn diagram and genes exclusively expressed in the MOMa group
--------------------------------------------------------------

In order to clarify the differential gene expression panels among the three groups, Venn diagram analysis was performed, and the results depicted the overlap of differentially expressed genes between the MO, Ma and MOMa groups ([Fig. 2](#f2-ijmm-43-02-0791){ref-type="fig"}). In total, 48 genes were upregulated and 8 were genes downregulated exclusively in the MOMa group. These genes were the candidates that participated in the reversal of morphine tolerance. It was also identified that 20 genes were upregulated and 13 genes were downregulated exclusively in the MO group; these genes were not altered by melatonin treatment, so these genes were not involved in the melatonin reversal effect in morphine tolerance. All the genes in Venn diagram analysis are listed in [Table IV-A and -B](#tIV-ijmm-43-02-0791){ref-type="table"}. Genes expressed exclusively in the MOMa group are notable as they may be the targets for the reversal of morphine tolerance associated with melatonin in future studies. From [Table IV-B](#tIV-ijmm-43-02-0791){ref-type="table"}, the myocilin gene demonstrated the greatest fold change in upregulation; and myocilin has been reported to mediate myelination in the peripheral nervous system ([@b26-ijmm-43-02-0791]). Furthermore, microtubule-associated protein 9 expression was decreased in the MOMa group, and this gene has been reported to serve a role in mitotic spindle formation and mitosis progression ([@b27-ijmm-43-02-0791]), implying the potential involvement of melatonin.

Reversed gene expression panel between MO/C and MOMa/C groups
-------------------------------------------------------------

In order to clarify which genes were altered by melatonin treatment in morphine-tolerant rats, genes from the microarray data with inverted gene expression profiles between MO/C and MOMa/C groups were selected. Hierarchical clustering analysis was performed to construct a reversed gene expression heatmap between the MO/C and MOMa/C groups ([Fig. 3](#f3-ijmm-43-02-0791){ref-type="fig"}). Genes were selected from the microarray data with the criteria of log~2~ ratio ≥1 or ≤−1 and P\<0.05, and the expression of the genes was reversed between the MO/C and MOMa/C groups. The constructed panel according to the heatmap of the reversed genes was listed in [Table V](#tV-ijmm-43-02-0791){ref-type="table"}. The panel with inverted gene expression may be used to investigate potential pathways derived by melatonin treatment.

PANTHER pathway mapping and RT-qPCR analysis
--------------------------------------------

The genes listed in [Table V-A and -B](#tV-ijmm-43-02-0791){ref-type="table"} were used for enrichment analysis by the PANTHER algorithm provided by the GO Consortium. The PANTHER pathway mapped 4 out of 29 genes for the genes listed in [Table V-A](#tV-ijmm-43-02-0791){ref-type="table"} and 10 out of 66 genes for the genes listed in [Table V-B](#tV-ijmm-43-02-0791){ref-type="table"}. The PANTHER-mapped pathways and associated genes are listed in [Table VI-A and -B](#tVI-ijmm-43-02-0791){ref-type="table"}. Guanine nucleotide binding protein β polypeptide 1 (Gnb1) was identified to participate in numerous cellular functions, including neuron-associated functions, including glutamatergic, cholinergic, GABAergic, dopaminergic, serotonergic and sympathetic neuron functions. Furthermore, Gnb1 has also been reported to participate in other pathways, including histamine H1 and H2 receptors and several hormone receptor signals. Gnb1 was upregulated 1.4-fold in the MO group and downregulated 1.3-fold in the MOMA group; this result implies the potential of a melatonin-mediated pathway via the repression of G~β~ expression and signaling. On the other hand, the genes mapped in [Table VI-B](#tVI-ijmm-43-02-0791){ref-type="table"} mainly participated in cell proliferation and migration in addition to cytoskeleton reconstruction. For example, a gene named inositol 1,4,5-trisphosphate receptor, type 3 (Itpr3) was downregulated 1.7-fold in the MO group but was upregulated 1.8-fold in the MOMA group. A number of pathways associated with Itpr3, including inflammatory, cell proliferation and migration, G protein mediated and vaso-relaxation pathways, were suggested. The genes mentioned in [Table VI-A](#tVI-ijmm-43-02-0791){ref-type="table"} and [VI-B](#tVI-ijmm-43-02-0791){ref-type="table"} were selected and their gene expressions were verified using RT-qPCR ([Fig. 4](#f4-ijmm-43-02-0791){ref-type="fig"}). All the genes selected here demonstrated an accordance with the expression trends of the microarray results. The results indicate the potential signaling pathways of melatonin in the rat spinal cord for the restoration of cell proliferation and migration through cytoskeleton reconstruction.

Discussion
==========

By using microarray analysis of rat spinal cords from different treatment groups, the gene expression alterations in different conditions were identified. Panels of gene expression with upregulation in the MO group but downregulation in the MOMa group and also inverted gene expression profiles between the MO/C and MOMa/C groups were constructed. Among them, a number of notable genes were identified following PANTHER pathway mapping. For example, Gnb1 is one of the three subunits of heterotrimeric guanine nucleotide binding proteins (G proteins), which integrate signals between G protein coupled receptors (GPCR) ([@b28-ijmm-43-02-0791]). GPCR signaling is initiated when a ligand-bound receptor activates heterotrimeric G proteins on the inner leaflet of the plasma membrane by catalyzing the exchange of GDP for GTP on G protein α subunit (Gα), causing it to release the Gβγ subunits. The GTP-bound Gα and free Gβγ subunits transmit the signal by engaging intracellular effector molecules until GTP is hydrolysed and the β subunits are recoupled to the α subunit to terminate signal transduction receptors and effectors ([@b29-ijmm-43-02-0791]). According to a study by Klein *et al* ([@b30-ijmm-43-02-0791]), Gnb1 belongs to a group of genes that is night/day differentially expressed in the pineal body; this result implies the potential involvement of Gnb1 in melatonin treatment. Furthermore, β-arrestin-2 mediated desensitization of the *µ*-opioid receptor is involved in morphine tolerance ([@b31-ijmm-43-02-0791],[@b32-ijmm-43-02-0791]). In the present data, Gnb1 was upregulated in the MO group but downregulated by melatonin treatment; this result indicates the potential of a role of melatonin in the activation and desensitization of GPCR.

Another gene, Itpr3, was downregulated in the MO group but upregulated in the MOMA group. It was also produced following PANTHER pathway mapping. Itpr3 is the receptor for inositol 1,4,5-trisphosphate (IP~3~), which mediates the release of intracellular calcium ([@b33-ijmm-43-02-0791]). Following IP~3~ binding, Itpr3 permits calcium flow out of the endoplasmic reticulum ([@b34-ijmm-43-02-0791]) and results in the activation of transient receptor potential cation channel subfamily M member 5, which results in membrane depolarization ([@b35-ijmm-43-02-0791]). In the case of melatonin treatment with Itpr3 upregulation, it was speculated that depolarization in certain nerve cells in the spinal cord may participate in the melatonin-derived attenuation of antinociceptive morphine tolerance.

In the present model, long-term morphine administration did not affect opioid receptor expression potentially due to the alteration of signal transduction and receptor-G protein coupling. It has been demonstrated that the downregulation of opioid receptors following chronic agonist exposure induces tolerance ([@b36-ijmm-43-02-0791],[@b37-ijmm-43-02-0791]). However, a controversial report did not observe the downregulation of opioid receptors in tolerant animals ([@b38-ijmm-43-02-0791]). On the other hand, studies suggest that β-arrestin-2 (Arrb2) binding causes OPR desensitization, and OPR endocytosis and recycling are required for receptor resensitization. This result suggests the potential involvement of Arrb2 with morphine tolerance ([@b31-ijmm-43-02-0791]). However, in the present data, the expression of Arrb2 between the groups was similar; the results did not support the potential involvement of Arrb2 with morphine tolerance. Combining the previous discussion with the present data, it was postulated that the expression changes of opioid receptor and Arrb2 are not mandatory for morphine tolerance mechanisms.

There are limitations in descriptive microarray studies. The first limitation is that sequences in the microarray will be refined in newer databases and will result in different outcomes. Secondly, the associations between mRNAs may be different between mice and humans ([@b39-ijmm-43-02-0791]). The third limitation is that the gene expression detected by microarrays is descriptive and may not reflect protein expression and subsequent post-transcriptional modifications ([@b40-ijmm-43-02-0791]). However, identifying changes in gene expression in tissues with a high-throughput approach remains a good option as it can be performed in one experiment. Even though the present study uses descriptive microarray analysis, a panel of genes that are specifically expressed in morphine-tolerant animals with or without melatonin treatment was produced. As it is impossible to collect the spinal cord from patients, therefore future studies will use drug databases to identify drugs which target the genes of interest in the present study and use the drugs in the same rat models as in the present study to assess the dosage and efficacy of the drug in the treatment of relieving the morphine tolerance. Following that, the drugs with efficacy in the rat model will be used in humans. Next, patients who are under chronic treatment and with morphine tolerance may be recruited to assess the efficacy of the drug in order to ascertain the results of the present and provide novel treatment methods. From the present microarray analysis, novel insight into the molecular profiles associated with morphine tolerance and the effects of melatonin was provided. The present study offers a foundation for future specific hypotheses testing on potential therapeutic targets derived from melatonin treatment in patients with long-term morphine exposure.
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![Experimental procedure and effect of melatonin on the antinocieptive effect in morphine-tolerant rats. (A) Experimental procedure for drug administration. Male Wistar rats were implanted with two i.t. catheters, one of which was connected to a mini-osmotic pump for the infusion of morphine or saline for 7 days. On day 7, subsequent to morphine tolerance development, the catheter was cut, and 3 h later the rats were injected intrathecally with either vehicle or melatonin via the second catheter. A total of 30 min later, a single dose of morphine (15 *µ*g) was injected intrathecally and its antinociceptive effect measured. (B) Melatonin reverses the antinociceptive effect of morphine in morphine-tolerant rats. Antinociception of morphine was assessed on day 7 following intrathecal infusion of saline or morphine. At 3 h subsequent to the discontinuation of infusion, the rats were injected intrathecally with 10% ethanol (as vehicle) or 50 *µ*g melatonin. After 30 min, the rats underwent a 15 *µ*g morphine administration, then tail-flick latency was measured every 30 min for 120 min. All data are presented as the mean ± standard error of the mean for at least 5 rats. ^\*\*^P\<0.01 vs. the Ma group; ^\#\#^P\<0.01 vs. the MO group. C, control (saline infusion/vehicle injection/saline challenge); MO, morphine (morphine infusion/vehicle injection/morphine challenge); Ma, melatonin (morphine infusion/melatonin injection/saline challenge); MOMa, (morphine infusion/melatonin injection/morphine challenge); i.t., intrathecal; qPCR, quantitative polymerase chain reaction.](IJMM-43-02-0791-g00){#f1-ijmm-43-02-0791}

![Venn diagram analysis of the genes that were upregulated (left) or downregulated (right) by morphine tolerance and/or melatonin treatment compared with the control group. In each pair test, the upregulated genes were identified as follows: Log~2~ \|Fold change\| ≥ 1 and P\<0.05 In the diagram, red circles represent genes putatively affected by long-term morphine application, yellow circles represent genes influenced by melatonin treatment and green circles represent genes for which melatonin-induced expression changes were putatively affected by morphine. All genes considered were differentially expressed compared with the untreated group. C, control (saline infusion/vehicle injection/saline challenge); MO, morphine (morphine infusion/vehicle injection/morphine challenge); Ma, melatonin (morphine infusion/melatonin injection/saline challenge); MOMa, (morphine infusion/melatonin injection/morphine challenge).](IJMM-43-02-0791-g01){#f2-ijmm-43-02-0791}

![Hierarchical clustering analysis of genes with expression completely inverted between the MO and MOMa group. Upregulated genes are indicated in red, and downregulated genes are presented in green. The signal intensity values of each sample were transformed to log~2~ values and subjected to hierarchical clustering using standard correlation. MO, morphine (morphine infusion/vehicle injection/morphine challenge); MOMa, (morphine infusion/melatonin injection/morphine challenge).](IJMM-43-02-0791-g02){#f3-ijmm-43-02-0791}

![Expressions of genes of interests determined by reverse transcription-quantitative polymerase chain reaction. All expression levels were normalized using GAPDH expression. ^\*^P\<0.05, ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001 with comparison shown by lines. MO, morphine (morphine infusion/vehicle injection/morphine challenge); MOMa, (morphine infusion/melatonin injection/morphine challenge); Gnb1, guanine nucleotide binding protein β polypeptide 1; Cckbr, cholecystokinin B receptor; Htr1a, 5-hydroxytryptamine receptor 1A; Itpr3, inositol 1,4,5-trisphosphate receptor type 3; Gtf2a1, general transcription factor IIA subunit 1; Per1, period circadian regulator 1; Col5a3, collagen type V α 3 chain; Lims2, LIM zinc finger domain containing 2; RasI1, RAS protein activator like 1, Dgkz, diaglycerol kinase ζ; Mat2a, methionine adenosyltransferase 2A.](IJMM-43-02-0791-g03){#f4-ijmm-43-02-0791}

###### 

Primers used for reverse transcription-quantitative polymerase chain reaction analysis.

  Target gene                                                Gene ID          Position                        Sequence
  ---------------------------------------------------------- ---------------- ------------------------------- -------------------------------
  G protein subunit β 1 (Gnb1)                               NM_030987.2      F:262-281                       5′-tccagtgggaagaatccaaa-3′
                                                             R:317-337        5′-ccagtgcatggcataaatctt-3′     
  Cholecystokinin B receptor (Cckbr)                         NM_013165.2      F:1799-1819                     5′-cccgtttgacttcattattgc-3′
                                                             R:1842-1861      5′-tgaaaggcgtgtggttgata-3′      
  5-hydroxytryptamine receptor 1A (Htr1a)                    NM_012585.1      F:1054-1072                     5′-ggcaccttcatcctctgct-3′
                                                             R:1110-1128      5′-gtggcagctgctttcacag-3′       
  RAS protein activator like 1 (Rasal1)                      NM_001108335.1   F:408-429                       5′-ggagtacactgttcaccttcca-3′′
                                                             R:451-470        5′-tcctcatccagcacgtagaa-3′      
  General transcription factor 2A subunit 1 like (Gtf2a1l)   NM_001012136.1   F:1222-1242                     5′-gaggatcccctaaattctgga-3′
                                                             R:1267-1289      5′-ttatctgtgtcaaacaggtctgg-3′   
  Period circadian clock 1 (Per1)                            NM_001034125.1   F:1986-2008                     5′-tcctaacacaaccaagcgtaaat-3′
                                                             R:2043-2062      5′-ccctctgcttgtcatcatca-3′      
  Methionine adenosyltransferase 2A (Mat2a)                  NM_134351.1      F:149-168                       5′-tgtaggggaaggtcatccag-3′
                                                             R:204-222        5′-cctgctgaaggtgtgcatc-3′       
  Collagen type V α 3 chain (Col5a3)                         NM_021760.1      F:634-652                       5′-cggggaggagtcttttgag-3′
                                                             R:673-693        5′-gcctgagggtctggaattaac-3′     
  Inositol 1,4,5-trisphosphate receptor, type 3 (Itpr3)      NM_013138.1      F:8362-8381                     5′-taggggatgcaagttctcca-3′
                                                             R:8403-8422      5′-ccactgagaaatgccagtca-3′      
  Diacylglycerol kinase ζ (Dgkz)                             NM_031143.1      F:330-347                       5′-ctttgggcacaggaaagc-3′
                                                             R:410-429        5′-gatctgccgctcagattcac-3′      
  LIM zinc finger domain containing 2 (Lims2)                NM_001012163.1   F:966-985                       5′-tcatgtgattgagggtgacg-3′
                                                             R:1032-1051      5′ccaccaggagaacagactgg-3′       

F, forward; R, reverse.

###### 

Number of differentially expressed genes.

  Group comparison   Upregulated   Downregulated
  ------------------ ------------- ---------------
  MO/C               162           16
  MOMa/C             290           15
  Ma/C               476           71

Standard selection criteria to identify differentially expressed genes are as follows: i) log~2~ \|Fold change\|≥1 and P\<0.05; ii) log~2~ ratios='NA' and the differences of intensity between the two samples ≥1000. Detail gene lists were be provided by request. C, control (saline infusion/vehicle injection/saline challenge); Mo, morphine (morphine infusion/vehicle injection/morphine challenge); Ma, melatonin (morphine infusion/melatonin injection/saline challenge); MOMa, (morphine infusion/melatonin injection/morphine challenge).

###### 

Identified gene ontology terms of the MO and MOMa groups compared with the C group.

  Geneset name                                                                                            MO/C   MOMa/C                         
  ------------------------------------------------------------------------------------------------------- ------ -------- -------- ----- ------ --------
  GO:0001846-opsonin binding                                                                                     N.I.              7     3      \<0.01
  GO:0001871-pattern binding                                                                              116    7        \<0.01   116   13     \<0.01
  GO:0001872-zymosan binding                                                                              3      2        0.02     3     2      0.04
  GO:0003924-GTPase activity                                                                              98     4        0.05           N.I.   
  GO:0003779-actin binding                                                                                       N.I.              233   10     0.01
  GO:0004857-enzyme inhibitor activity                                                                    238    10       \<0.01   238   11     \<0.01
  GO:0004859-phospholipase inhibitor activity                                                             6      2        0.05           N.I.   
  GO:0004866-endopeptidase inhibitor activity                                                             148    6        0.01     148   7      0.02
  GO:0005125-cytokine activity                                                                            110    5        0.01           N.I.   
  GO:0005506-iron ion binding                                                                             289    7        0.03     289   10     0.03
  GO:0005525-GTP binding                                                                                  312    8        0.02           N.I.   
  GO:0005509-calcium ion binding                                                                                 N.I.              672   20     0.01
  GO:0005529-sugar binding                                                                                       N.I.              215   9      0.02
  GO:0005539-glycosaminoglycan binding                                                                    102    5        0.01     102   11     \<0.01
  GO:0008009-chemokine activity                                                                           32     5        \<0.01   32    4      0.01
  GO:0008201-heparin binding                                                                              72     4        0.02     72    8      \<0.01
  GO:0016175-superoxide-generating                                                                               N.I.              7     3      \<0.01
  NADPH oxidase activity                                                                                                                        
  GO:0016814\~hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines   22     3        0.01     22    4      \<0.01
  GO:0019239-deaminase activity                                                                                  N.I.              21    3      0.04
  GO:0019001-guanyl nucleotide binding                                                                    326    8        0.02           N.I.   
  GO:0019763-immunoglobulin receptor activity                                                             7      3        \<0.01   7     3      \<0.01
  GO:0019770-IgG receptor activity                                                                        4      2        0.03           N.I.   
  GO:0019834-phospholipase A2 inhibitor activity                                                          3      2        0.02     3     2      0.04
  GO:0019863-IgE binding                                                                                  4      2        0.03           N.I.   
  GO:0019864-IgG binding                                                                                  6      4        \<0.01   6     4      \<0.01
  GO:0019865-immunoglobulin binding                                                                       12     5        \<0.01   12    5      \<0.01
  GO:0019955-cytokine binding                                                                             87     4        0.04     87    7      \<0.01
  GO:0020037-heme binding                                                                                 148    5        0.04     148   7      0.02
  GO:0030246-carbohydrate binding                                                                         337    10       \<0.01   337   20     \<0.01
  GO:0030247-polysaccharide binding                                                                       116    7        \<0.01   116   13     \<0.01
  GO:0030414-peptidase inhibitor activity                                                                 159    7        \<0.01   159   8      0.01
  GO:0032403-protein complex binding                                                                             N.I.              222   12     \<0.01
  GO:0032561-guanyl ribonucleotide binding                                                                326    8        0.02           N.I.   
  GO:0042379-chemokine receptor binding                                                                   33     5        \<0.01   33    4      0.01
  GO:0042802-identical protein binding                                                                    588    11       0.02     588   18     0.01
  GO:0042803-protein homodimerization activity                                                            318    8        0.02     318   15     \<0.01
  GO:0046906-tetrapyrrole binding                                                                         154    5        0.04     154   7      0.03
  GO:0046983-protein dimerization activity                                                                528    10       0.03     528   20     \<0.01
  GO:0048020-CCR chemokine receptor binding                                                               3      2        0.02           N.I.   
  GO:0050664-oxidoreductase activity, acting on NADH or NADPH, with oxygen as acceptor                           N.I.              11    3      0.01

N.I., not identified; Ig, immunoglobulin; GO, Gene Ontology; C, control (saline infusion/vehicle injection/saline challenge); Mo, morphine (morphine infusion/vehicle injection/morphine challenge); Ma, melatonin (morphine infusion/melatonin injection/saline challenge); MOMa, (morphine infusion/melatonin injection/morphine challenge).

###### 

Top 20 exclusively upregulated and downregulated genes in each group.

  A, Exclusively expressed genes in MO group                                                                                                           
  -------------------------------------------- ------------------------------------------------------------------------------------------- ----------- ------------
  Ddx60                                        DEAD (Asp-Glu-Ala-Asp) box polypeptide 60, probable ATP-dependent RNA helicase DDX60-like   100360801   1.61 Up
  Lgals3bp                                     Lectin, galactoside-binding, soluble, 3 binding protein                                     245955      1.54 Up
  Oas1a                                        2′-5′ oligoadenylate synthetase 1A                                                          192281      1.47 Up
  Isg15                                        ISG15 ubiquitin-like modifier                                                               298693      1.46 Up
  Slamf9                                       SLAM family member 9                                                                        289235      1.29 Up
  Usp18                                        Ubiquitin specific peptidase 18                                                             312688      1.28 Up
  Smim5                                        Small integral membrane protein 5                                                           689926      1.26 Up
  Casp4                                        Caspase 4, apoptosis-related cysteine peptidase                                             114555      1.2 Up
  Cd33                                         CD33 molecule                                                                               690492      1.2 Up
  Pik3ap1                                      Phosphoinositide-3-kinase adaptor protein 1                                                 294048      1.14 Up
  Ccl7                                         Chemokine (C-C motif) ligand 7                                                              287561      1.13 Up
  Apol9a                                       Apolipoprotein L 9a                                                                         503164      1.11 Up
  Dpt                                          Dermatopontin                                                                               289178      1.09 Up
  Cryaa                                        Crystallin, αA                                                                              24273       1.06 Up
  Irgm                                         Immunity-related GTPase family, M                                                           303090      1.05 Up
  Irf7                                         Interferon regulatory factor 7                                                              293624      1.04 Up
  Gpr160                                       G protein-coupled receptor 160                                                              499588      1.03 Up
  Uba7                                         Ubiquitin-like modifier activating enzyme 7                                                 301000      1.03 Up
  Vwa5b1                                       Von Willebrand factor A domain containing 5B1                                               313653      1.03 Up
  Olr104                                       Olfactory receptor 104                                                                      293243      1.02 Up
  LOC689064                                    β-globin                                                                                    689064      −1 Down
  Fras1                                        Fraser syndrome 1                                                                           289486      −1.01 Down
  Zfp597                                       Zinc finger protein 597                                                                     266774      −1.06 Down
  LOC681849                                    Similar to protein C6orf142 homolog                                                         681849      −1.09 Down
  Alas2                                        Aminolevulinate, delta-, synthase 2                                                         25748       −1.13 Down
  LOC500300                                    Similar to hypothetical protein MGC6835                                                     500300      −1.2 Down
  Hspa1b                                       Heat shock 70 kD protein 1B (mapped)                                                        294254      −1.21 Down
  Ccdc77                                       Coiled-coil domain containing 77                                                            312677      −1.3 Down
  Oas1e                                        2′-5′ oligoadenylate synthetase 1E                                                          494201      −1.4 Down
  Pmp2                                         Peripheral myelin protein 2                                                                 688790      −1.47 Down
  Fkbp6                                        FK506 binding protein 6                                                                     288597      −1.98 Down
  Prx                                          Periaxin                                                                                    78960       −2.16 Down
  Mpz                                          Myelin protein zero                                                                         24564       −2.92 Down

  B, Exclusively expressed genes in MOMa group                                                                             
  ---------------------------------------------- ---------------------------------------------------------------- -------- ------------
  Myoc                                           Myocilin                                                         81523    2.47 Up
  Samsn1                                         SAM domain, SH3 domain and nuclear localization signals, 1       170637   1.48 Up
  Scin                                           Scinderin                                                        298975   1.45 Up
  Ncan                                           Neurocan                                                         58982    1.35 Up
  Tagln                                          Transgelin                                                       25123    1.34 Up
  Aplnr                                          Apelin receptor                                                  83518    1.31 Up
  Nlrc4                                          NLR family, CARD domain containing 4                             298784   1.28 Up
  S1pr3                                          Sphingosine-1-phosphate receptor 3                               306792   1.27 Up
  Mxra8                                          Matrix-remodelling associated 8                                  313770   1.26 Up
  Sptbn5                                         Spectrin, β, non-erythrocytic 5                                  296090   1.24 Up
  Plin2                                          Perilipin 2                                                      298199   1.23 Up
  Epyc                                           Epiphycan                                                        314772   1.23 Up
  Chdh                                           Choline dehydrogenase                                            290551   1.22 Up
  Hlx                                            H2.0-like homeobox                                               364069   1.19 Up
  Cenpf                                          Centromere protein F                                             257649   1.19 Up
  Aoah                                           Acyloxyacyl hydrolase (neutrophil)                               498757   1.17 Up
  Spta1                                          Spectrin, α, erythrocytic 1 (elliptocytosis 2)                   289257   1.15 Up
  Trim47                                         Tripartite motif-containing 47                                   690374   1.14 Up
  Abi3                                           ABI family, member 3                                             303476   1.13 Up
  Ssc5d                                          Scavenger receptor cysteine rich domain containing (5 domains)   308341   1.13 Up
  Epm2aip1                                       EPM2A (laforin) interacting protein 1                            316021   −1.02 Down
  LOC691921                                      Hypothetical protein LOC691921                                   691921   −1.04 Down
  Klhl11                                         Kelch-like 11 (*Drosophila*)                                     287706   −1.09 Down
  Ppargc1b                                       Peroxisome proliferator-activated receptor γ, coactivator 1 β    291567   −1.11 Down
  Pcdhb6                                         Protocadherin β6                                                 291653   −1.14 Down
  Tox2                                           TOX high mobility group box family member 2                      311615   −1.22 Down
  Map9                                           Microtubule-associated protein 9                                 310544   −1.26 Down
  RGD1309108                                     Similar to hypothetical protein FLJ23554                         315578   −1.55 Down

  C, Exclusively expressed genes in Ma group                                                                                                                  
  -------------------------------------------- -------------------------------------------------------------------------------------------------- ----------- ------------
  Defb3                                        β-defensin 3                                                                                       641623      3.52 Up
  RT1-Da                                       RT1 class II, locus Da                                                                             294269      2.60 Up
  RT1-Ba                                       RT1 class II, locus Ba                                                                             309621      2.59 Up
  Pxmp4                                        Peroxisomal membrane protein 4                                                                     282634      2.46 Up
  RT1-Bb                                       RT1 class II, locus Bb                                                                             309622      2.21 Up
  Ccl11                                        Chemokine (C-C motif) ligand 11                                                                    29397       2.08 Up
  Tmem252                                      Transmembrane protein 252                                                                          361744      2.07 Up
  Aurkb                                        Aurora kinase B                                                                                    114592      1.99 Up
  Cd74                                         Cd74 molecule, major histocompatibility complex, class II invariant chain                          25599       1.89 Up
  Birc5                                        Baculoviral IAP repeat-containing 5                                                                64041       1.81 Up
  Lmcd1                                        LIM and cysteine-rich domains 1                                                                    494021      1.80 Up
  Fam111a                                      Family with sequence similarity 111, member A                                                      499322      1.79 Up
  RSA-14-44                                    RSA-14-44 protein                                                                                  297173      1.77 Up
  Kif11                                        Kinesin family member 11                                                                           171304      1.70 Up
  Vdac1                                        Voltage-dependent anion channel 1                                                                  83529       1.70 Up
  Hmgn3                                        High mobility group nucleosomal binding domain 3                                                   113990      1.69 Up
  Nalcn                                        Sodium leak channel, non-selective                                                                 266760      1.69 Up
  Tnfrsf14                                     Tumor necrosis factor receptor superfamily, member 14                                              366518      1.67 Up
  Pex11a                                       Peroxisomal biogenesis factor 11 α                                                                 85249       1.61 Up
  RGD1564664                                   Similar to LOC387763 protein                                                                       499839      1.61 Up
  LOC100911604                                 CD99 antigen-like protein 2-like, similar to MIC2L1                                                500410      −1.14 Down
  Serpinb1b                                    Serine (or cysteine) peptidase inhibitor, clade B member 1b, leukocyte elastase inhibitor A-like   306891      −1.15 Down
  Mgll                                         Monoglyceride lipase                                                                               29254       −1.15 Down
  Lrtomt                                       Leucine rich transmembrane and 0-methyltransferase domain containing                               308868      −1.16 Down
  Tas2r145                                     Taste receptor, type 2, member 145                                                                 100363053   −1.18 Down
  Kcnip3                                       Kv channel interacting protein 3, calsenilin                                                       65199       −1.19 Down
  Fbll1                                        Fibrillarin-like 1                                                                                 363563      −1.19 Down
  LOC100910054                                 NF-κ-B-repressing factor-like                                                                      100910054   −1.20 Down
  Ttll1                                        Tubulin tyrosine ligase-like family, member 1                                                      362969      −1.21 Down
  Negr1                                        Neuronal growth regulator 1                                                                        59318       −1.22 Down
  Ttll11                                       Tubulin tyrosine ligase-like family, member 11                                                     689746      −1.24 Down
  Mgam                                         Maltase-glucoamylase                                                                               312272      −1.25 Down
  Apba1                                        Amyloid β(A4) precursor protein-binding, family A, member 1                                        83589       −1.26 Down
  Hoxb5                                        Homeo box B5                                                                                       497987      −1.26 Down
  Zfp238                                       Zinc finger protein 238                                                                            64619       −1.27 Down
  Ddx6                                         DEAD (Asp-Glu-Ala-Asp) box helicase 6                                                              500988      −1.29 Down
  LOC310902                                    Similar to Alcohol dehydrogenase 1A (alcohol dehydrogenase α subunit)                              310902      −1.30 Down
  Fgf13                                        Fibroblast growth factor 13                                                                        84488       −1.32 Down
  Tnnc2                                        Troponin C type 2 (fast)                                                                           296369      −1.33 Down
  Pdyn                                         Prodynorphin                                                                                       29190       −1.43 Down

log2 (Ratio) Mo, morphine (morphine infusion/vehicle injection/morphine challenge); Up, upregulated; Down, downregulated.

###### 

Genes with inverted expressions between Mo and MOMa group

  A, Genes with upregulated expression in the MO group but downregulated expression in the MOMa group                                                                                       
  ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----------- ------ ------
  Glra1                                                                                                 Glycine receptor, α1                                             25674       2.10   0.65
  Olr1595                                                                                               Olfactory receptor 1595                                          304990      1.70   0.66
  Ndufaf1                                                                                               NADH dehydrogenase (ubiquinone) complex I, assembly factor 1     296086      1.42   0.72
  RGD1563091                                                                                            Similar to OEF2                                                  500011      1.40   0.79
  Gnb1                                                                                                  Guanine nucleotide binding protein (G protein), βpolypeptide 1   24400       1.40   0.76
  Ccdc122                                                                                               Coiled-coil domain containing 122                                100360752   1.39   0.61
  Csta                                                                                                  Cystatin A (stefin A)                                            288067      1.35   0.70
  Blvra                                                                                                 Biliverdin reductase A                                           116599      1.33   0.70
  MGC114464                                                                                             Similar to expressed sequence AI836003                           500925      1.32   0.75
  LOC100910655                                                                                          Paralemmin-2-like                                                100910655   1.31   0.64
  Dync1i1                                                                                               Dynein cytoplasmic 1 intermediate chain 1                        29564       1.31   0.79
  LOC685007                                                                                             Similar to unc-93 homolog A                                      685007      1.30   0.68
  Cckbr                                                                                                 Cholecystokinin B receptor                                       25706       1.29   0.78
  Art4                                                                                                  ADP-ribosyltransferase 4                                         312806      1.29   0.72
  Zbtb41                                                                                                Cytochrome C oxidase assembly factor 5                           503252      1.28   0.75
  Cnga4                                                                                                 Cyclic nucleotide gated channel α4                               85258       1.28   0.78
  Thg1l                                                                                                 tRNA-histidine guanylyltransferase 1-like (*S. cerevisiae*)      303067      1.26   0.82
  Mettl11b                                                                                              Methyltransferase like 11B                                       289167      1.25   0.68
  LOC100911235                                                                                          Mediator of RNA polymerase II transcription subunit 7-like       100911235   1.25   0.81
  Htr1a                                                                                                 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled   24473       1.24   0.75
  Pou3f2                                                                                                POU class 3 homeobox 2                                           29588       1.24   0.77

  B, Genes with downregulated expression in the MO group but upregulated expression in the MOMa group                                                                           
  ----------------------------------------------------------------------------------------------------- ------------------------------------------------------- -------- ------ ------
  Itpr3                                                                                                 Inositol 1,4,5-trisphosphate receptor, type 3           25679    0.59   1.82
  Mocs1                                                                                                 Molybdenum cofactor synthesis 1                         301221   0.69   1.66
  Col5a3                                                                                                Collagen, type V, α3                                    60379    0.73   1.66
  Mrc1                                                                                                  Mannose receptor, C type 1                              291327   0.66   1.65
  Lims2                                                                                                 LIM and senescent cell antigen like domains 2           361303   0.65   1.63
  Gtf2a1l                                                                                               General transcription factor IIA, 1-like                316711   0.76   1.58
  Olr1147                                                                                               Olfactory receptor 1147                                 300408   0.60   1.55
  Ccnt2                                                                                                 Cyclin T2                                               304758   0.82   1.51
  Map3k6                                                                                                Mitogen-activated protein kinase kinase kinase 6        313022   0.64   1.45
  Tnfrsf25                                                                                              Tumor necrosis factor receptor superfamily, member 25   500592   0.71   1.43
  Slc41a1                                                                                               Solute carrier family 41, member 1                      363985   0.83   1.43
  Mvb12b                                                                                                Multivesicular body subunit 12B                         362118   0.80   1.42
  Acaca                                                                                                 Acetyl-CoA carboxylase α                                60581    0.77   1.38
  Ryr3                                                                                                  Ryanodine receptor 3                                    170546   0.77   1.38
  Col27a1                                                                                               Collagen, type XXVII, α1                                298101   0.83   1.36
  Rasal1                                                                                                RAS protein activator like 1 (GAP1 like)                360814   0.72   1.36
  Rasal1                                                                                                RAS protein activator like 1 (GAP1 like)                360814   0.72   1.36
  Mat2a                                                                                                 Methionine adenosyltransferase II                       690510   0.79   1.29
  er1                                                                                                   Period circadian clock 1                                287422   0.63   1.25
  Dgkz                                                                                                  Diacylglycerol kinase ζ                                 81821    0.77   1.24

Mo, morphine (morphine infusion/vehicle injection/morphine challenge); MOMa, (morphine infusion/melatonin injection/morphine challenge).

###### 

PANTHER pathway mapped cellular functions of four selected genes from [Table V-A and -B](#tV-ijmm-43-02-0791){ref-type="table"}.

  A, PANTHER pathway mapped cellular functions of four selected genes from [Table V-A](#tV-ijmm-43-02-0791){ref-type="table"}                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ---------------------------------------------------------------------------
  Guanine nucleotide binding protein, β polypeptide 1 (Gnb1)                                                                    Neuron                                                                           
  Pain_Relief_anagelsia                                                                                                         Opioid proopiomelanocortin pathway                                               
  Pain_Relief_anagelsia                                                                                                         Opioid proenkephalin pathway                                                     
  Pain_Relief_anagelsia                                                                                                         Enkephalin release                                                               
  Pain_Relief_anagelsia                                                                                                         Cortocotropin releasing factor receptor signaling pathway                        
  Pain_Relief_anagelsia                                                                                                         Opioid prodynorphin pathway                                                      
  Glutamertergic                                                                                                                Metabotropic glutamate receptor group II pathway                                 
  Glutamertergic                                                                                                                Heterotrimeric G-protein signaling pathway-rod outer segment phototransduction   
  Glutamertergic                                                                                                                Metabotropic glutamate receptor group III pathway                                
  Cholinergic                                                                                                                   Muscarinic acetylcholine receptor 1 and 3 signaling pathway                      
  Cholinergic                                                                                                                   β1 adrenergic receptor signaling pathway                                         
  Cholinergic                                                                                                                   Muscarinic acetylcholine receptor 2 and 4 signaling pathway                      
  GABAergic                                                                                                                     GABA-B_receptor_II_signaling                                                     
  GABAergic                                                                                                                     Endogenous_cannabinoid_signaling                                                 
  Dopaminergic                                                                                                                  Dopamine receptor mediated signaling pathway                                     
  Serotonergic                                                                                                                  5HT2 type receptor mediated signaling pathway                                    
  Serotonergic                                                                                                                  5HT4 type receptor mediated signaling pathway                                    
  Depolarization                                                                                                                Nicotine pharmacodynamics pathway                                                
  Sympathetic                                                                                                                   β3 adrenergic receptor signaling pathway                                         
  G protein mediated pathway                                                                                                    β2 adrenergic receptor signaling pathway                                         
  Inflammation                                                                                                                                                                                                   
  G protein mediated pathway                                                                                                    Histamine H1 receptor mediated signaling pathway                                 
  G protein mediated pathway                                                                                                    Histamine H2 receptor mediated signaling pathway                                 
  G protein mediated pathway                                                                                                    Heterotrimeric G-protein signaling pathway-Gq a and Go α mediated pathway        
  G protein mediated pathway                                                                                                    Thyrotropin-releasing hormone receptor signaling pathway                         
  Others                                                                                                                                                                                                         
  Signaling pathway                                                                                                             Gonadotropin releasing hormone receptor pathway                                  
  Signaling pathway                                                                                                             PI3 kinase pathway                                                               
  Signaling pathway                                                                                                             Wnt signaling pathway                                                            
  Angiogenesis                                                                                                                  Angiotensin II-stimulated signaling through G proteins and β-arrestin            
  Muscle contraction                                                                                                            Oxytocin receptor mediated signaling pathway                                     
  Cell migration                                                                                                                CCKR signaling pathway                                                           
  Cholecystokinin B receptor (Cckbr)                                                                                            Cell migration                                                                   CCKR signaling pathway
  5-hydroxytryptamine (serotonin) receptor 1A                                                                                   Neuron_Serotonergic                                                              5HT1 type receptor mediated signaling pathway
  G protein-coupled (Htr1a)                                                                                                     G protein mediated pathway                                                       Heterotrimeric G-protein signaling pathway-Gi α and Gs α mediated pathway
  Dynein cytoplasmic 1 intermediate chain 1 (Dync1i1)                                                                           Neuron                                                                           Huntington disease

  B, PANTHER pathway mapped cellular functions of four selected genes from [Table V-B](#tV-ijmm-43-02-0791){ref-type="table"}                                                                               
  ----------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------
  Inositol 1,4,5-trisphosphate receptor type 3 (Itpr3)                                                                          Inflammation and immunity                                                   Inflammation mediated by chemokine and cytokine signaling pathway
                                                                                                                                Histamine H1 receptor mediated signaling pathwayB cell activation           
  Cell proliferation and migration                                                                                              Gonadotropin releasing hormone receptor pathway                             
                                                                                                                                Wnt signaling pathway                                                       
                                                                                                                                Muscarinic acetylcholine receptor 1 and 3 signaling pathway                 
                                                                                                                                PDGF signaling pathway                                                      
  G protein mediated pathway                                                                                                    Angiotensin II-stimulated signaling through                                 
                                                                                                                                G proteins and β-arrestin                                                   
                                                                                                                                Heterotrimeric G-protein signaling pathway-Gq α and Go α mediated pathway   
  Vaso relaxation                                                                                                               Endothelin signaling pathway                                                
  RAS protein activator like 1 (Rasal1)                                                                                         Cell proliferation and migration                                            FGF signaling pathway
                                                                                                                                EGF receptor signaling pathway                                              
                                                                                                                                PDGF signaling pathway                                                      
  General transcription factor subunit 1-like (Gtf2a1l)                                                                         Transcription regulation                                                    Transcription regulation by bZIP transcription 2A
                                                                                                                                General transcription regulation                                            
  Period circadian protein                                                                                                      Biochemical oscillator                                                      Circadian clock system
  homolog 1 (Per1)                                                                                                              Cell proliferation and migration                                            Gonadotropin releasing hormone receptor pathway
  S-adenosylmethionine synthase isoform type-2 (Mat2a)                                                                          Enzyme activity                                                             S adenosyl methionine biosynthesis
  Diacylglycerol kinase ζ (Dgkz)                                                                                                Cell proliferation and migration                                            Gonadotropin releasing hormone receptor pathway
  α4 type V collagen (Col5a3)                                                                                                   Cytoskeleton                                                                Integrin signaling pathway
  Collagen α-1(XXVII) chain (Col27a1)                                                                                           Cytoskeleton                                                                Integrin signaling pathway
  LIM and senescent cell antigen-like-containing domain protein (Lims2)                                                         Cytoskeleton                                                                Integrin signaling pathway
  Mitogen-activated protein kinase kinase kinase 6 (Map3k6)                                                                     Cell proliferation and migration                                            FGF signaling pathway

[^1]: Contributed equally
